AVN-101

AVN-101, a close structural analogue of latrepirdine, is a selective 5-HT6 receptor antagonist which is under development by Avineuro Pharmaceuticals for the treatment of Alzheimer's disease and anxiety disorders.[1][2][3] As of November 2013, it is in phase II clinical trials for these indications.[2][3][4]

AVN-101
Identifiers
CAS Number
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC21H24N2
Molar mass304.437 g·mol−1
3D model (JSmol)

See also

References
  1. Ivachtchenko V, Ivanenkov Y (2013). "Small Molecule 5-HT6R Ligands: A Comprehensive Insight into their Selectivity and Activity". Current Bioactive Compounds. 9 (1): 64–100. doi:10.2174/1573407211309010007. ISSN 1573-4072.
  2. Griebel G, Holmes A (September 2013). "50 years of hurdles and hope in anxiolytic drug discovery". Nature Reviews. Drug Discovery. 12 (9): 667–87. doi:10.1038/nrd4075. PMC 4176700. PMID 23989795.
  3. Benhamú B, Martín-Fontecha M, Vázquez-Villa H, Pardo L, López-Rodríguez ML (September 2014). "Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease". Journal of Medicinal Chemistry. 57 (17): 7160–81. doi:10.1021/jm5003952. PMID 24850589.
  4. "AVN 101". AdisInsight. Retrieved 2015-06-10.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.